Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT230-6 vs Standard of Care in Advanced Soft Tissue Sarcomas
NCT06263231Phase 3Recruiting
- Sponsor
- Intensity Therapeutics
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of INT230-6 in soft tissue sarcoma (STS), sponsored by Intensity Therapeutics. Started Jun 2024; status: recruiting.
02
Drugs
INT230-6
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06263231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263231.